RepliCel Life Sciences (TSE:RP) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
RepliCel Life Sciences has announced the sale of its assets and licensing of patent rights to 1456390 B.C. Ltd, a company controlled by RepliCel’s CEO Andrew Schutte. The deal is seen as the best path forward for maximizing shareholder return and commercializing the assets. The agreement includes an 8% royalty on gross profits from the commercialized products, promising a potential value increase for shareholders.
For further insights into TSE:RP stock, check out TipRanks’ Stock Analysis page.